Search

Your search keyword '"Hermida S."' showing total 110 results

Search Constraints

Start Over You searched for: Author "Hermida S." Remove constraint Author: "Hermida S."
110 results on '"Hermida S."'

Search Results

1. IGF1R Plays a Protective Role in Pneumococcal Pneumonia

2. DOP74 Short and long-term effectiveness and safety of ustekinumab in Ulcerative Colitis in real life: the ULISES study

3. P744 Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding

5. 1074P Peripheral low-density neutrophils identify a subset of NSCLC patients with high PD-L1 tumor expression that can benefit from chemo-immunotherapy

6. 40P Identification of a PD-1/LAG-3 co-expression profile in human tumor-infiltrating T cells uncovers a T cell dysfunctionality genetic regulated programme

7. Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

8. Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis

12. Circulating Low Density Neutrophils Are Associated with Resistance to First-Line Anti-PD1/PDL1 Immunotherapy in Non-Small Cell Lung Cancer

13. P545 Safety of ustekinumab in pregnant patients with inflammatory bowel disease and in their offspring: results from the DUMBO registry of GETECCU

14. P550 Management of immunomodulators and biologic agents in pregnant patients with inflammatory bowel: results from the DUMBO registry of GETECCU

15. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

19. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

20. Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial

21. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics

23. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

24. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

25. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

28. El cultivo del ramio

32. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study.

33. Empowering CO 2 Eco-Refrigeration With Colossal Breathing-Caloric-Like Effects in MOF-508b.

34. Modulation of the Dynamics of a Two-Dimensional Interweaving Metal-Organic Framework through Induced Hydrogen Bonding.

35. Polymorphism and orientation control of copper-dicarboxylate metal-organic framework thin films through vapour- and liquid-phase growth.

36. Vapor-assisted synthesis of the MOF-74 metal-organic framework family from zinc, cobalt, and magnesium oxides.

37. Plasma fractalkine contributes to systemic myeloid diversity and PD-L1/PD-1 blockade in lung cancer.

38. [Management of genetic renal disorders: local experience and importance of the network].

39. Telomerase deficiency and dysfunctional telomeres in the lung tumor microenvironment impair tumor progression in NSCLC mouse models and patient-derived xenografts.

40. Leading Edge: Intratumor Delivery of Monoclonal Antibodies for the Treatment of Solid Tumors.

41. In-vitro inhalation bioavailability estimation of Metal(oid)s in atmospheric particulate matter (PM 2.5 ) using simulated alveolar lysosomal fluid: A dialyzability approach.

42. Cutting-Edge CAR Engineering: Beyond T Cells.

43. Vapor-Assisted Powder Synthesis and Oriented MOF-CVD Thin Films of the Metal-Organic Framework HKUST-1.

44. Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy.

45. Vapor-Phase Loading of an Ionic Liquid into a Zeolitic Imidazolate Framework.

46. IGF1R is a mediator of sex-specific metabolism in mice: Effects of age and high-fat diet.

47. Consequences of telomere dysfunction in fibroblasts, club and basal cells for lung fibrosis development.

48. Immune Profiling Uncovers Memory T-Cell Responses with a Th17 Signature in Cancer Patients with Previous SARS-CoV-2 Infection Followed by mRNA Vaccination.

49. How Can We Improve Vaccination Response in Old People? Part I: Targeting Immunosenescence of Innate Immunity Cells.

50. How Can We Improve the Vaccination Response in Older People? Part II: Targeting Immunosenescence of Adaptive Immunity Cells.

Catalog

Books, media, physical & digital resources